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Abstract 
The present investigation in Sprague-Dawley rats (SD) was designed to examine effects of 
astaxanthin (Asta) at different doses on elevated blood pressure (BP) and glucose-insulin 
perturbations produced by heavy sucrose ingestion. We also examined effects of Asta on BP 
during restraint stress. SD were divided into six groups each containing eight rats. All SD ate 
a basic diet of ground regular rat chow with sucrose added at 30% w/w. The Control group 
received only the basic diet containing added sucrose, while the other five groups each re-
ceived the same diet with added test material: captopril, (30 mg/Kg), pioglitazone (15.0 
mg/Kg), low Asta (25 mg/Kg), medium Asta (50 mg/kg) or high Asta (100 mg/Kg). Many tests 
were carried out to examine the mechanisms behind the effects of Asta on BP (serum ACE 
activity, losartan challenge, and LNAME challenge) and the glucose-insulin system (glucose 
tolerance, HOMA measurement, and insulin challenge). In SD, a relatively low dose of Asta 
decreased SBP, but produced no major changes in the glucose-insulin system simulating re-
sults from a previous study using Zucker Fatty Rats. Increasing the dose of Asta resulted in 
both a lowering of elevated systolic BP and enhanced insulin sensitivity determined by many 
different estimations. BP lowering was consistent with changes in the renin-angiotensin (RAS) 
and nitric oxide (NO) systems. At the examined doses of each, captopril lowered BP in SD 
without influencing glucose-insulin metabolism, whereas pioglitazone favorably affected glu-
cose-insulin metabolism while showing essentially no effects on BP. Accordingly, Asta bene-
ficially affects both sucrose-induced elevations of BP and insulin resistance at relatively high 
doses in SD. Also, Asta at higher doses lessens restraint stress, whereas, captopril and 
pioglitazone did not at the doses examined, even though they influenced the BP and glu-
cose-insulin systems respectively. 
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INTRODUCTION 
In a recent study examining effects of astaxan-
thin (Asta) on elevated blood pressure (BP) and glu-
cose-insulin perturbations in Zucker Fatty Rats (ZFR), 
we found under conditions examined that this carot-
enoid at the doses under investigation lowered sys-
tolic BP (SBP) consistently, but had no significant in-
fluences  on  glucose-insulin  metabolism  [1].  Our 
findings in the ZFR, considered by many to be an ex-
cellent model of the Metabolic Syndrome [2-4], raised 
two  difficulties  in  interpreting  the  data:  (1)  studies 
from other laboratories had found that Asta amelio-
rates both BP elevations and glucose-insulin pertur-Int. J. Med. Sci. 2011, 8 
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bations  [5]  and  (2)  previous  reports  had  strongly 
suggested  that  hypertension  and  other  chronic  dis-
turbances  making  up  the  Metabolic  Syndrome  are 
driven by the development of insulin resistance [5-7]. 
Plausible explanations for the first disparity are the 
differences in dosing and/or rat species used among 
the various studies. Concerning the second need for 
clarification, further corroboration of the lack of direct 
dependence  between  insulin  resistance  and  hyper-
tension is necessary to substantiate this possibility. 
Accordingly, the purpose of the present investi-
gation was to compare with our original results the 
effects  of  Asta  at  different  doses  and  in  a  different 
species of rat, Sprague-Dawley (SD), on BP and glu-
cose-insulin perturbations. As a secondary gain, we 
wished to determine whether Asta ameliorates other 
forms of stress similar to previous findings with heat 
stress [1]. 
MATERIAL AND METHODS 
Protocol 
 The Animal Welfare Board at Georgetown Uni-
versity Medical Center approved the protocol for this 
investigation. Forty-eight male Sprague-Dawley rats 
(SD),  obtained  from  Taconic  Farms,  Germantown, 
NY, were used. The SD, weighing between 252-324 g 
at the beginning of the studies, were housed in a con-
stant temperature room with a light-dark phase of 12 
hours each. The SD were divided into six groups, each 
containing eight rats. The Control group received only 
the basic diet containing the added sucrose, while the 
other  five  groups  each  received  the  basic  diet  with 
added sucrose containing on a weight of chow basis: 
captopril,  (30  mg/Kg),  pioglitazone  (15.0  mg/Kg), 
low Asta (25 mg/Kg), medium Asta (50 mg/kg) or 
high Asta (100 mg/Kg). The amount of Asta added 
was  based  on  2%  w/w  content  of  astaxanthin  to 
Haematococcus pluvialis powder
1. 
The SD were followed for  approximately eight 
months while consuming their respective diets. Body 
weights and SBP were routinely measured. At the two 
month and eight month periods of study, specialized 
tests [intraperitoneal glucose-tolerance (ipGTT), insu-
lin-challenge  (ICT),  losartan  challenge,  homeostatic 
model assessment (HOMA-IR), and Nw-nitro-L argi-
nine-methyl ester hydrochloride (LNAME) challenge] 
along with blood chemistry assessments were carried 
out. Details of the procedures are given below. 
                                                       
1 Fuji Chemical Industry Co., Ltd., Toyama 930-0397, Japan 
– AstaREAL P2 
 
Body Weight (BW)  
 BW  was  estimated  by  routine  scale  measure-
ments. Two reading taken at least 10 minutes apart on 
the  given  day  had  to  be  within  two  grams  of  each 
other or the procedure was repeated until the weights 
were consistently within the two gram range. 
Food and Water Intake 
 Food and water intakes were estimated close to 
the midpoint of the study (Day 121) by subtracting the 
volume  or  weight  of  the  remaining  fluid  and  food 
from the amounts premeasured 24 hours earlier. 
Blood Pressure (BP)  
 SBP was measured by tail plethysmography [8] 
using two different instruments. As in many of our 
previous  studies  and  for  the  majority  of  our  meas-
urements, we used an instrument from Narco Biosci-
ences (Houston, TX) [9,10]. This allowed us to rapidly 
measure SBP with a beeper sound system. The second 
reading  was  performed  on  an  instrument  obtained 
from  Kent  Scientific  Corporation  (Torrington,  CT). 
This is a computerized, non-invasive tail cuff acquisi-
tion system that utilizes a specially designed differ-
ential pressure transducer to non-invasively measure 
the blood volume in the tail. The latter instrument not 
only allowed us to record SBP, but also diastolic BP 
(DBP), mean BP (MBP), and cardiac rate. A previous 
report showed that the SBP readings were essentially 
similar between the two instruments [11]. Rats were 
allowed free access to their diet and water until SBP 
and the other cardiovascular readings were obtained 
after a slight warming between 13.00 h and 17.00 h. 
Multiple readings on individual rats at each session 
were taken. To be accepted, SBP measurements on a 
given rat had to be virtually stable. Over the course of 
study,  readings  were  recorded  at  multiple  time 
points.  
In most cases, the following tests were carried 
out at two (weeks 7-9) and eight (weeks 31-33) months 
to give an acute and sub chronic reading. 
Blood Chemistries  
Blood for chemical analysis was obtained at two 
and eight months following removal of food the night 
before. Chemistry data were obtained via dry chem-
istry procedures using a Johnson and Johnson Vitros 
250 instrument. The glucose and insulin levels from 
the fasting bloods were used to derive a homeostatic 
model assessment (HOMA-IR) value to assess insulin 
sensitivity [12]. Immunoreactive rat insulin  was de-
termined  on  fasting  blood  specimens  by  radioim-
munoassay  (Diagnostic  Products  Corporation,  Los 
Angeles CA).  Int. J. Med. Sci. 2011, 8 
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Intraperitoneal glucose tolerance test (ipGTT)  
 During the ipGTT, performed at two and eight 
months,  glucose  (2.5  g/Kg  BW)  was  injected  intra-
peritoneally  (i.p.)  to  challenge  tolerance.  Drops  of 
blood were obtained from the rat tail at 0, 15, 30, 60, 
and  120  minutes  post  injection.  Statistical  compari-
sons of serum glucose were made by differences from 
initial baseline in area under the curve (AUC) over the 
two  hours  of  study.  Glucose  was  estimated  using 
commercial glucose strips (Lifescan, One Touch Ultra, 
Melitas, CA).  
Insulin Challenge Testing (ICT)  
 Testing  was  commenced  after  17-19  hours  of 
food deprivation at two and eight months. For ICT, 
0.6 unit of regular insulin/kg BW (Eli Lilly Co., Indi-
anapolis, IN) was administered intraperitoneally (i.p.) 
to determine the decrease in glucose levels from the 
initial baseline. Blood for glucose determinations was 
obtained from the tail vein at 7.5 minutes after injec-
tion.  Glucose  was  estimated  using  commercial  glu-
cose strips (Lifescan, One Touch Ultra, Melitas, CA). 
At the two months level, a variation of this procedure 
was carried out where both glucose 250 mg/Kg and 
0.6 units of regular insulin/kg were injected simulta-
neously,  and  the  glucose  rise  above  baseline  was 
measured. In the first test, a greater decrease in glu-
cose levels soon after insulin injection before various 
checks  and  balances  can  come  into  significant  play 
suggests  greater  sensitivity;  and  in  the  second  pro-
cedure, a lesser early elevation in circulating glucose 
after glucose challenge suggests greater sensitivity to 
insulin. 
Losartan Challenge  
 This test using the angiotensin receptor blocker, 
losartan,  was  also  performed  at  two  and  eight 
months. After performing baseline SBP readings, SD 
from all dietary groups were given 20 mg/kg losartan 
orally via gastric lavage [13]. Three and six hours after 
lavage, SBP was remeasured. The decreased SBP after 
losartan was used to estimate activity of the RAS with 
a greater decrease in SBP connoting augmented sys-
tem activity [14]. Previous studies established that the 
lowest values of BP reached a plateau for a couple of 
hours after the 6h mark.  
Serum angiotensin converting enzyme (ACE) Activity  
 ACE  refers  to  the  angiotensin  converting  en-
zyme.  ACE,  necessary  for  the  production  of  angio-
tensin 2 which is chiefly responsible for the presser 
effect in the RAS system,  was measured by a com-
mercial kit (Sigma Co. Ltd, St. Louis, MO) [15]. This 
spectrophotometric  method  utilizes  the  synthetic 
tripeptide  substrate  N-[3-(2-furyl)acryloyl]-- 
phenylalanylglcylglcine (FAPGG). FAPGG is hydro-
lyzed  by  ACE  to  furylacryloylphenylalanine  (FAP) 
and glycylglycine. Hydrolysis of FAPGG results in a 
decreased absorbency at 340 nm. Serum ACE activity 
was  determined  by  comparing  the  sample  reaction 
rate to that obtained with an appropriate ACE cali-
brator.  
Nw-nitro-L arginine-methyl ester hydrochloride (LNAME) 
Challenge 
 Effects of nitric oxide synthase (NOS) inhibition 
on SBP were measured [13]. After baseline measure-
ments  of  SBP,  the  NOS  inhibitor  Nw-nitro-L  argi-
nine-methyl ester hydrochloride (LNAME) was given 
intraperitoneally (i.p.) at a dose of 10 mg/kg. Each rat 
received a single dose of LNAME. Measurements of 
SBP were taken at four, seven, 10, 15, and 20 minutes 
post  injection.  The  area  under  the  curve  relative  to 
baseline was used to estimate activity of the NO sys-
tem  with  a  greater  increase  in  SBP  connoting  aug-
mented system activity. 
Statistical Analyses 
   Results are presented as mean + SEM. SBP 
and BW were examined by repeated measures, 2-way 
analyses of variance (one factor being group and the 
second  factor  being  time  of  examination).  Where  a 
significant effect of regimen was detected by repeated 
measures  ANOVA  (p<0.05),  the  Dunnett  t  test  was 
used  to  establish  which  differences  between  means 
reached  statistical  significance  [16].  When  the  data 
from  two  columns  were  analyzed  at  a  single  time 
point, Student’s t test was used. Statistical significance 
was set at a p < 0.05. 
 
RESULTS 
Body Weight (Fig.1) 
There  was  a  steady  increase  in  mean  body 
weight in all groups over the eight months of study in 
these SD (Fig. 1). Examining the overall data over the 
course  of  study  shows  that  the  changes  in  weight 
were  reasonably  similar  in  all  groups  during  the 
study  with  no  statistically  significant  differences  at 
any time point. 
Food and Water Intake (Table 1) 
The  food  and  water  consumption  two  months 
into the study and at the end of study are depicted in 
Table 1. There were no significant differences in the 
24-hour food ingestion, and water intake was similar 
in  all  groups  with  the  exception  of  the  SD  taking 
captopril in their food at two months. These rats had a Int. J. Med. Sci. 2011, 8 
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lower average water intake compared to Control that 
was not seen at eight months. The Pioglitazone group 
showed a trend toward a higher water intake at eight 
months. 
 
 
Figure 1. Body weight (BW) of SD in Control, Captopril, Pioglitazone, Low, Medium. High Astaxanthin groups over the 
course of study. Data are expressed as average + SEM. 
 
Table 1.  Food and Water Intake 
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Blood Chemistries (Table 2) 
 Data are given for blood chemistry values at two 
months and at eight months. At two months, serum 
creatinine was significantly elevated in the Low Asta 
and Medium Asta groups. CO2 was decreased in Me-
dium Asta group, and there was a trend for low cal-
cium in the Low Asta group compared to Control. At 
eight months, none of these same  significant differ-
ences  were  seen.  However,  the  circulating  levels  of 
glucose  were  statistically  significantly  lower  in  the 
Pioglitazone group, and a trend was present for the 
High Asta group (p=.096) compared to Control. While 
lower, the mean value for the Medium Asta group did 
not attain statistical significance. None of the values 
for the other 12 chemistries at the eight months eval-
uation showed statistically significant differences. 
Table 2. Blood Chemistries  
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Figure 2. HOMA-IR values at the end of two months. * indicates groups significantly different from Control. Mean + SEM 
depicted. n=8 in each group. 
 
Homeostatic Model Assessment (HOMA-IR) Analysis: (Fig 
2) 
 At two months, blood was also drawn to meas-
ure insulin levels. Average circulating insulin levels in 
each group reported as ng/ml + SEM were as follows: 
Control  1.36+.08,  Captopril  1.23+.06,  Pioglitazone 
0.94+.05,  Low Asta 1.21+.10, Medium Asta 1.01+.07, 
and High Asta 1.00+.07.  The values for the Pioglita-
zone,  Medium  and  High  Asta  groups  were  statisti-
cally  significantly  lower  than  Control.    When  con-
verted to HOMA-IR units, a commonly used means to 
assess insulin sensitivity [12], the same groups were 
still  significantly lower  than Control  suggesting en-
hanced insulin sensitivity compared to Control (Fig 
2). 
Intraperitoneal Glucose Tolerance Test (ipGTT) (Table 3) 
 At  two  months,  area  under  the  curve  (AUC) 
above initial baseline values for the one-hour ipGTT 
was lowest in the High Asta group and was statisti-
cally  significantly  different  from  Control.  Values  in 
the Pioglitazone group showed a trend toward being 
significantly  lower.  At  eight  months,  the  average 
values for the area under the curve (AUC) were sig-
nificantly  lower  in  the  Pioglitazone,  Medium  and 
High Asta groups. 
Insulin Challenge Test (ICT) (Table 4) 
 Both  the  control  and  treatment  groups  were 
challenged with intraperitoneal (i.p.) regular insulin. 
At two months, 15 minutes after regular insulin chal-
lenge, the decrease in circulating glucose levels was 
significantly greater in the Pioglitazone, Medium and 
High Asta groups compared to Control. Results were 
near similar when the procedure was repeated at 8 
months.  The  only  difference  was  that  the  Medium 
Asta  group  showed  only  a  trend  toward  statistical 
significance  this  time.  A  variation  of  this  challenge 
was  undertaken  at  the  two  month  time.  With  the 
combined  challenges  with  insulin  and  glucose,  the 
levels of circulating glucose above initial baseline at 
7.5 minutes were as follows: Control 77.3 mg/dl + 4.7 
(SEM); Captopril 68.1 mg/dl + 4.5 (SEM), Pioglitazone 
59.5 mg/dl + 3.1 (SEM); Low Asta 66.9 mg/dl + 3.8 
(SEM);  Medium  Asta  65.0  mg/dl  +  4.2  (SEM)  and 
High Asta 54.9 mg/dl + 3.0 (SEM). Compared to con-
trol,  these  values  were  statistically  significantly  dif-
ferent in the Pioglitazone and High Asta groups.  
 Int. J. Med. Sci. 2011, 8 
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Table 3. 60 Minute GTT at 2 and 8 Months (AUC) 
 
Table 4. ICT at 2 and 8 Months (Decrease in glucose concentration [mg/dl] at 7.5 minutes after insulin injections) 
 
 
 
 
Blood Pressure (Fig. 3a, 3b, Table 5) 
 Although the SBP of all groups were obtained 
simultaneously, for clarity, we show the data for the 
Captopril and Pioglitazone groups separately (Fig. 3a) 
from the three test groups, Low, Medium and High 
Asta groups (Fig. 3b). The values for the same, single 
Control group are depicted in each figure. The aver-
age SBP readings of the Control group rose steadily 
over  the  initial  three  to  four  months  of  the  present 
study and then leveled off around 150 mm Hg over 
the last few months. Fig. 3a shows that the average 
SBP of the group receiving captopril decreased sig-
nificantly within the first few days . The relatively low 
readings of this group continued over the 8 months of 
study.  Those  SD  in  the  Pioglitazone  group  showed 
virtually no change from Control throughout the re-
mainder of the study. The readings in the High Asta 
group  were  significantly  lower  for  the  majority  of 
readings (Fig.3b). While the tendency was for the SBP 
readings to be lower in the Low Asta group compared 
to the Control group, only three of the last readings 
reached statistical significance.  
The  average  readings  for  the  Medium  Asta 
group fell between the high and low groups – con-
sistently significantly lower than Control over the last 
three months. 
The  entire  BP  profile  and  heart  rate  were  as-
sessed at the end of the study as shown in Table 5. 
Measured by another method, the SBP were compa-
rable to the previous readings and remained signifi-
cantly lower in the Captopril and High Asta groups Int. J. Med. Sci. 2011, 8 
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compared to control, with the lowest average read-
ings  in  the  Captopril  group.  Likewise,  the  average 
diastolic (DBP) and mean BP (MBP) were significantly 
lower in the same two groups compared to Control. 
There were no significant  differences in the cardiac 
rate among groups. 
 
Figure 3. a) Systolic blood pressure (SBP) of SD in Control, Captopril, and Pioglitazone groups over a period of 120 days. 
b) SBP of SD in Control, Low, Medium and High Asta groups. Control is same in a and b. n=8 in each group. Data are 
expressed as mean ± SEM. Int. J. Med. Sci. 2011, 8 
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Table 5. Kent BP Readings at 8 Months  
 
Table 6. Effects on RAS at 2 and 8 Months  
   
 
 
 
Renin-Angiotensin System (RAS)(Table 6) 
 SD  challenged  with  losartan  showed  signifi-
cantly  less  decrease  in  SBP  in  the  Pioglitazone  and 
High Asta groups compared to Control at two and 
eight months (Table 6). At two months compared to 
Control, the lesser decrease in activity in the Captopril 
group was a trend, while no other group showed any 
significant differences from Control. At eight months, 
the  Captopril,  and  Medium  and  High  Asta  groups 
developed  significantly  lesser  decreases  in  activity 
compared to Control.  
At two months, the serum angiotensin convert-
ing  enzyme  (ACE)  activity  in  the  Captopril  group 
showed a trend toward lesser activity when compared 
to Control. However, at eight months the Captopril, 
Medium and Low Asta groups were statistically sig-
nificantly lower than Control. 
Effect of LNAME on SBP (Fig 4) 
Twenty  minutes  after  LNAME  injection,  there 
was a statistically significant increased area under the 
curve (AUC) compared to Control for the Captopril, 
and High Asta groups. 
Effects of Restraint Stress on Systolic Blood Pressure (Fig 
5a, 5b) 
 These studies were carried out in the first month 
of study. Within the first 15 minutes after the SD were 
confined in tightly-fitting, plastic tubes normally used 
to measure tail blood pressure, the SBP of the Control 
group rose roughly 15 mm Hg, began to decline to 10 
mm Hg at 30 minutes and were near baseline after 45 
minutes (Fig 5a). The groups of SD receiving Capto-
pril and Pioglitazone essentially showed the same SBP 
change with this constraint stress as Control. The Low 
Asta  group  showed  essentially  the  same  pattern, 
whereas, the values for the Medium and High Asta 
groups were significantly lower at the 15 and 30 mi-
nute marks (Fig 5b). To evaluate the data differently, 
we calculated the area under the curve (AUC) relative 
to initial baseline for each group. The results were as 
follows: Control 369 + 31.6 (SEM), Captopril 339 + 26.6 
(SEM), Pioglitazone 409 + 45.9 (SEM), Low Asta 345 + 
27.0 (SEM), Medium Asta 253 + 46.3 (SEM), and High 
Asta 277 + 30.4 (SEM). The values for the Medium and 
High  Asta  group  were  significantly  different  from 
Control. 
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Figure 4. Response to L NAME challenge among various groups. Increase in SBP from baseline over 30 minutes after i.p. 
challenge with LNAME. The Captopril and Hi Asta groups were significantly different (*) from control over 30 minutes. n=8 
in each group. Data are expressed as mean ± SEM. 
 
 
Figure 5. a) Systolic blood pressure (SBP) of SD in Control, Captopril, and Pioglitazone groups undergoing restraint stress. 
b) SBP of SD in Control, Low, Medium and High Asta groups undergoing restraint stress. Control is same in a and b. n=8 in 
each group. Data are expressed as mean ± SEM. Int. J. Med. Sci. 2011, 8 
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DISCUSSION 
 Astaxanthin has been described as “a carotenoid 
with potential in human  health and nutrition” [17]. 
This  is  largely  because  astaxanthin,  a  substance 
providing red color to many living organisms such as 
salmon,  lobsters,  and  shrimp,  exhibits  strong  free 
radical scavenging activity by protecting against lipid 
peroxidation  and  oxidative  damage  of 
LDL-cholesterol,  cell  membranes,  cells,  and  tissues 
[17-19].  The  unique  structure  of  the  terminal  ring 
moiety  is  probably  behind  the  efficient  antioxidant 
activity of the naturally occurring carotenoid pigment 
[20]. 
 An  earlier  investigation  reported  that  astaxan-
thin  ameliorates  insulin  resistance  [5],  which  seems 
reasonable in light of an association of antioxidants in 
general  with  insulin  sensitivity  [21].  However,  we 
were unable to show this coupling of events in our 
previous investigation of astaxanthin in Zucker Fatty 
Rats  (ZFR)  [1].  In  that  investigation,  we  found  that 
astaxanthin could overcome blood pressure elevated 
by  excess  sucrose  ingestion  despite  no  apparent 
changes in the glucose-insulin system. This observa-
tion intrigued us, because a general belief is that the 
major driving force behind various components of the 
Metabolic  Syndrome  is  insulin  resistance.  This,  of 
course, should include hypertension [5-7]. 
In 1980, we first reported that consuming high 
levels of sucrose unrelated to changes in sodium in-
take by three species of rats increased systolic blood 
pressure significantly [9]. At that time, little had been 
written  concerning  the  role  of  sucrose  ingestion  in 
hypertension  [22].  Follow  up  investigations  eventu-
ally  established  that  “sugar-induced  blood  pressure 
elevations”  occurred  in  other  rats  species  [10],  and 
showed that fructose and sucrose compared to glu-
cose were more effective in raising blood pressure [23] 
and that the pressure effects coincided with the duel 
presence of insulin resistance [24]. A direct link be-
tween insulin resistance and elevated SBP was made 
stronger  when  we  found  that  trivalent  chromium 
could overcome sucrose-induced elevations of systolic 
blood  pressure  [25].  The  only  generally  recognized 
action of chromium at that time was to sensitize the 
insulin system [26,27]. This seemed to strengthen the 
hypothesis that insulin resistance had, at least in part, 
a  direct  association  with  elevated  blood  pressures 
caused  by  heavy  sugar  ingestion.  Therefore,  it  was 
quite surprising to find that astaxanthin could lower 
the  SBP  induced  by  high  sucrose  ingestion,  even 
though evidence of increased insulin sensitivity was 
not found [1].  
Why the differences in the effects of astaxanthin 
between the two studies [1,5]? At least, two possible 
reasons  exist:  dissimilar  responses  of  the  different 
species used (Spontaneously Hypertensive Rats [SHR] 
vs. ZFR) and/or the differing dosages of astaxanthin 
used [1,5]. Concerning dosing, Hussein et al. [5] re-
ported that astaxanthin gavaged at 50 mg/kg/day for 
22  weeks  significantly  reduced  arterial  blood  pres-
sure, fasting blood sugar, and homeostatic model as-
sessment (HOMA-IR) values. The latter two parame-
ters suggest improved insulin sensitivity. Based upon 
body  weight  and  the  conversion  factor  for  surface 
area in rats [28,29] that will be explained below, the 
dose of 50 mg/Kg/day is roughly equivalent to 500 
mg  daily  for  a  70  Kg  human.  However,  the  usual 
recommended daily dose of astaxanthin for humans is 
between 2-12 mg -- closer to the dose in our first study 
[1]. 
How did we arrive at our dosing schedule [1]? 
The doses of astaxanthin added to the food were ini-
tially based on a ratio of body weights: comparing a 
500 g rat to a 70 Kg human (conversion by weight = 
X140). However, many believe it is more appropriate 
to consider surface area rather than body weight in 
calculating dosing as mentioned above. The conver-
sion factor for surface area for a rat compared to a 
human is times seven (X7) [28,29], which makes the 
equivalency factor in our study X20 rather than X140. 
Since  we  estimated  that  rats  eat  approximately  25 
grams  of  food  per  day,  the  desired  daily  dose  was 
placed in that amount of food. Throughout the origi-
nal study [1], the food and water intakes among the 
different dietary groups seemed similar – suggesting 
that the ZFR were consuming near the desired daily 
doses. We added the astaxanthin to the diet at 5 and 
25  mg/Kg  [1].  Thus,  at  5  mg/Kg  in  the  food,  ZFR 
would eat about 0.125 mg daily and multiplied by 20, 
this would approximate a human dose of 2.5 mg dai-
ly. At 25 mg/Kg, the rats would eat five times more 
astaxanthin  –  roughly  equivalent  to  a  human  daily 
dose of 12.5 mg daily. 
To test our reasoning that the rat species and/or 
dosing  could  be  responsible  for  the  differences  be-
tween studies [1,5], we simultaneously examined both 
parameters -- species and dosing. First, we used a rat 
species different from ZFR i.e., the commonly studied 
Sprague-Dawley (SD) albino rat. Second, in addition 
to using the same dose as previously (equivalent to a 
human dose of 12.5 mg/daily) in one group [1], we 
also increased the doses to levels comparable to hu-
man levels of 25 and 50 mg daily in two others. While 
not as high as in the previous study [5], still, these 
doses far exceed comparable doses recommended in 
humans.  Int. J. Med. Sci. 2011, 8 
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At  the  low  dose  of  astaxanthin  in  the  present 
study (similar to the previously used one simulating a 
human daily dose of 12.5 mg [1]), we again saw es-
sentially no effects on the glucose-insulin system in 
the SD; but we were able to see some lowering of the 
elevated  sucrose-induced  blood  pressure  rise  (Fig, 
3b). This mirrors the previous situation in the ZFR. At 
the highest level used (50 mg human equivalent), we 
were  clearly  able  to  show  in  SD  enhanced  insulin 
sensitivity  in  addition  to  lowered  blood  pressure 
readings (Fig. 3b). A dose-response was apparent, as 
results were consistently better as doses of astaxan-
thin were increased in the feed. Thus, dose rather than 
rat species was more important in explaining dispar-
ity in previous results [1,5]. The examined doses did 
not  affect  food-water  intake  and  body  weight  and 
caused no apparent toxicities judged by blood chem-
istry values and observations of well-being. 
Although the results with astaxanthin answered 
our  original  question,  those  with  captopril  and 
pioglitazone, the positive controls, raised others. Our 
results did not indicate an effect of captopril on insu-
lin sensitivity, or an effect of pioglitazone on blood 
pressure. Captopril has been reported to enhance in-
sulin sensitivity [30,31], and pioglitazone was previ-
ously found to lower blood pressure in fructose-fed 
rats [32]. Nevertheless, captopril, a well known ACE 
inhibitor [30],  did not influence significantly any  of 
the measured parameters that would suggest changes 
in insulin sensitivity, even though it lowered blood 
pressure. Based upon our findings, rather than insulin 
resistance, the blood pressure results could be due, at 
least in part, to changes in activity of the RAS and NO 
systems. The latter conclusion is based upon results 
from the losartan challenge, measurements of serum 
ACE activity, and the LNAME challenge tests. Lam et 
al postulated that the effect captopril on insulin sensi-
tivity  may  be  due  to  inhibiting  production  and/or 
release of endothelin-1, as well as blocking the ren-
in-angiotensin and kinin systems [31]. 
The data from the Pioglitazone group were just 
the  opposite  of  those  from  the  Captopril  group  – 
showing significant enhancement of insulin sensitiv-
ity  but  essentially  no  influence  on  elevated  blood 
pressure.  This  also  suggests  that  insulin  resistance 
does  not  necessarily  cause  hypertension  directly  in 
sucrose-induced elevations of blood pressure, a pos-
tulate proposed by Buchanan et al in their examina-
tion of the influences of pioglitazone in vivo in fruc-
tose-fed rats [32]. They reported a decrease in blood 
pressure by pioglitazone that was unrelated to fasting 
plasma insulin levels at a dose of pioglitazone of 400 
mg/Kg – approximately 25 times greater than what 
we used here. While we did not show a direct effect 
between  the  status  of  insulin  sensitivity  and  blood 
pressure,  still  the  possibility  is  that  we  could  have 
shown that both drugs worked on the two systems at 
higher doses similar to the findings with astaxanthin. 
Previously,  we  found  fortuitously  in  ZFR  that 
astaxanthin  ameliorated  the  harmful  effects  of  heat 
stress [1]. Nishikawa et al [33] examined the ability of 
astaxanthin to overcome stress-induced gastric ulcers 
in rats. Ulcer indices were smaller with the rat group 
fed  astaxanthin  compared  to  control.  Two  United 
States patents discussed the ability of astaxanthin to 
be  an  anti  stress  agent  [34,35].  Accordingly,  we 
wished to expand the data on astaxanthin and stress 
by examining its effects on restraint stress. Similar to 
studies  with  heat  stress  [1],  astaxanthin  at  the  two 
higher doses did show significant ability to overcome 
the  blood  pressure  elevation  arising  from  restraint 
stress (Fig. 5b). The ability of captopril and pioglita-
zone to affect blood pressure and insulin sensitivity 
respectively but not restraint stress suggests that high 
dose astaxanthin does not influence restraint stress in 
a  major  fashion  via  the  renin-  angiotensin  nor  glu-
cose-insulin systems, at least not individually (Fig.5a). 
In conclusion, astaxanthin was able to affect both 
the renin-angiotensin, nitric oxide and glucose-insulin 
systems at relatively high doses. This carotenoid also 
ameliorated restraint stress at high doses. The data in 
the  Captopril  and  Pioglitazone  groups  suggest  that 
the anti stress effect of astaxanthin on rats are not re-
lated  to  influences  on  the  RAS,  NO,  nor  glu-
cose-insulin systems. 
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